Cargando…
Sodium-Glucose Cotransporter-2 Inhibitor versus Beta-Blocker Use for Hepatocellular Carcinoma Risk among People with Hepatitis B or C Virus Infection and Diabetes Mellitus
SIMPLE SUMMARY: The authors used a large Taiwanese database of patients with chronic hepatitis B or C in order to study if SGLT2I, as compared to BB, may decrease HCC. In brief, SGLT2I caused a risk reduction in the likelihood of HCC development of about 73%. ABSTRACT: Objective: The current study d...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10093089/ https://www.ncbi.nlm.nih.gov/pubmed/37046765 http://dx.doi.org/10.3390/cancers15072104 |